A pre-clinical stage biotechnology company developing in vivo genomic medicines for a variety of disease indications.

Ensoma has developed an in vivo cellular engineering platform that enables genetic editing of immune and blood cells to treat a variety of diseases across cancer, autoimmune, and inherited conditions. The company seeks to provide an “off-the-shelf” alternative to current cell therapy approaches through a single outpatient injection that avoids the need for cell collection and lengthy manufacturing processes. Ensoma’s technology is based on the academic work of its scientific co-founders Hans-Peter Kiem, M.D., Ph.D., Director of Stem Cell and Gene Therapy Program at the Fred Hutchinson Cancer Center, and André Lieber, M.D., Ph.D., of the University of Washington School of Medicine.